Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Ovarian Neoplasms

  Free Subscription


Articles published in Proc Natl Acad Sci U S A

Retrieve available abstracts of 14 articles:
HTML format
Text format



Single Articles


    March 2019

  1. Correction for Li et al., Mutational landscape of primary, metastatic, and recurrent ovarian cancer reveals c-MYC gains as potential target for BET inhibitors.
    Proc Natl Acad Sci U S A. 2019 Mar 11. pii: 1902633116.
    PubMed     Text format    


    February 2019
  2. WU X, Luo Q, Zhao P, Chang W, et al
    MGMT-activated DUB3 stabilizes MCL1 and drives chemoresistance in ovarian cancer.
    Proc Natl Acad Sci U S A. 2019 Feb 4. pii: 1814742116.
    PubMed     Text format     Abstract available


    January 2019
  3. ZHAO Y, Cao J, Melamed A, Worley M, et al
    Losartan treatment enhances chemotherapy efficacy and reduces ascites in ovarian cancer models by normalizing the tumor stroma.
    Proc Natl Acad Sci U S A. 2019 Jan 18. pii: 1818357116.
    PubMed     Text format     Abstract available


  4. GARTUNG A, Yang J, Sukhatme VP, Bielenberg DR, et al
    Suppression of chemotherapy-induced cytokine/lipid mediator surge and ovarian cancer by a dual COX-2/sEH inhibitor.
    Proc Natl Acad Sci U S A. 2019 Jan 15. pii: 1803999116.
    PubMed     Text format     Abstract available


    December 2018
  5. LI C, Bonazzoli E, Bellone S, Choi J, et al
    Mutational landscape of primary, metastatic, and recurrent ovarian cancer reveals c-MYC gains as potential target for BET inhibitors.
    Proc Natl Acad Sci U S A. 2018 Dec 24. pii: 1814027116.
    PubMed     Text format     Abstract available


    June 2018
  6. SUN X, Wang X, Tang Z, Grivainis M, et al
    Transcription factor profiling reveals molecular choreography and key regulators of human retrotransposon expression.
    Proc Natl Acad Sci U S A. 2018;115:E5526-E5535.
    PubMed     Text format     Abstract available


    May 2018
  7. SEO A, Steinberg-Shemer O, Unal S, Casadei S, et al
    Mechanism for survival of homozygous nonsense mutations in the tumor suppressor gene BRCA1.
    Proc Natl Acad Sci U S A. 2018;115:5241-5246.
    PubMed     Text format     Abstract available


    March 2018
  8. DI MODUGNO F, Caprara V, Chellini L, Tocci P, et al
    hMENA is a key regulator in endothelin-1/beta-arrestin1-induced invadopodial function and metastatic process.
    Proc Natl Acad Sci U S A. 2018;115:3132-3137.
    PubMed     Text format     Abstract available


  9. PATIL P, Parmigiani G
    Training replicable predictors in multiple studies.
    Proc Natl Acad Sci U S A. 2018;115:2578-2583.
    PubMed     Text format     Abstract available


  10. PURAYIL HT, Daaka Y
    beta-Arrestin1 mediates hMENA expression and ovarian cancer metastasis.
    Proc Natl Acad Sci U S A. 2018 Mar 7. pii: 1802643115.
    PubMed     Text format    


    December 2017
  11. STONE ML, Chiappinelli KB, Li H, Murphy LM, et al
    Epigenetic therapy activates type I interferon signaling in murine ovarian cancer to reduce immunosuppression and tumor burden.
    Proc Natl Acad Sci U S A. 2017 Dec 4. pii: 1712514114.
    PubMed     Text format     Abstract available


    August 2017
  12. KODAMA M, Kodama T, Newberg JY, Katayama H, et al
    In vivo loss-of-function screens identify KPNB1 as a new druggable oncogene in epithelial ovarian cancer.
    Proc Natl Acad Sci U S A. 2017 Aug 15. pii: 201705441.
    PubMed     Text format     Abstract available


    January 2017
  13. TANG Z, Steranka JP, Ma S, Grivainis M, et al
    Human transposon insertion profiling: Analysis, visualization and identification of somatic LINE-1 insertions in ovarian cancer.
    Proc Natl Acad Sci U S A. 2017 Jan 17. pii: 201619797.
    PubMed     Text format     Abstract available


    April 2016
  14. MENGHI F, Inaki K, Woo X, Kumar PA, et al
    The tandem duplicator phenotype as a distinct genomic configuration in cancer.
    Proc Natl Acad Sci U S A. 2016;113:E2373-82.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Ovarian Neoplasms is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: